Ignite Creation Date:
2024-05-06 @ 12:45 PM
Last Modification Date:
2024-10-26 @ 1:03 PM
Study NCT ID:
NCT03832153
Status:
WITHDRAWN
Last Update Posted:
2022-03-03
First Post:
2019-01-27
Brief Title:
Pan-Cardio-Genetics Clot Assessment in Acute Coronary Syndromes
Sponsor:
Aristotle University Of Thessaloniki
Organization:
Aristotle University Of Thessaloniki
Study Overview
Official Title:
Pan-Cardio-Genetics Clot Assessment in Acute Coronary Syndromes
Status:
WITHDRAWN
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
LACK OF FUNDING
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PGCA-ACS
Brief Summary:
Acute myocardial infarction with ST elevation STEMI is one of the leading causes of mortality Although the presence of thrombus in STEMI patients has been linked to adverse outcomes routine thrombus aspiration has not been proven effective A potential explanation could be that patients with STEMI should be risk-stratified Thus a more personalized approach in treating these patients is stressfully required This proposal aims to establish the required interdisciplinary infrastructure for developing a risk-stratification model by implementing clinical laboratory and angiographic data with molecular knowledge obtained by using innovative technologies such as data from nanomicro-Computed tomography and circulating microRNAs Two hundred consecutive patients with STEMI undergoing thrombus aspiration will be enrolled in the study and will be followed-up for one year for Major Adverse Cardiac and Cerebrovascular events MACCE The proposed approach will shed light on the pathophysiological mechanisms and broaden the investigators understanding of the complex cellular and molecular interactions in the STEMI setting that along with clinical parameters affect patient outcomes Furthermore it will enable the identification of certain circulating micro-RNAs as cardiovascular disease biomarkers and it will help clinicians to better stratify the cardiovascular and cerebrovascular risk of patients with STEMI As part of the work important characteristics of aspirated thrombi will be assessed for the first time such as volume density and shape and will be linked to patient outcomes All this information will be incorporated into one in-vitro model which will be developed using bioprinting and microfluidics methodologies The in-vitro model will facilitate i the in-depth exploration of the pathophysiological mechanisms in patients with STEMI and ii the therapeutic optimization of innovative nanocarriersnanomedicines with thrombolytic efficacy Clearly the study improves personalized cardiovascular medicine approaches by considering individual patient clinical assessment in a way that empowers the precision in diagnosis and therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None